VP, Biosimilars-U.S. Commercial

Lupin•Franklin Township, NJ

18d

About The Position

Vice President of Commercial, Biosimilars Vice President, Commercial – U.S. Biosimilars & 505(b)(2) As Vice President, Commercial – U.S. Biosimilars & 505(b)(2), you will lead the strategic development, launch, and growth of Lupin’s U.S. biosimilars and differentiated 505(b)(2) portfolio. This executive leader will drive market expansion, ensure profitable product positioning, and build commercial excellence across the organization. The role will shape go‑to‑market strategies that accelerate revenue growth, deepen market penetration, and position Lupin as a competitive force in complex and specialty pharmaceutical markets. This position requires a forward‑thinking enterprise builder who can translate deep market insight into strong cross‑functional execution.

Requirements

Bachelor’s degree in Life Sciences or Business; MBA or equivalent preferred.
12+ years of progressive commercial experience in generics, biosimilars, and/or 505(b)(2) pharmaceuticals.
Deep understanding of the U.S. payer and provider landscape.
Ability to navigate regulatory nuances specific to generics and hybrid pathways.
Executive presence and a history of leading high-performing commercial teams.

Nice To Haves

Experience with digital marketing and data-driven decision-making.
Familiarity with 340B, 505B2, GPOs, and institutional customer segments.
Ability to navigate ambiguity and drive results in a competitive market.
Demonstrated success in launching and optimizing performance for complex assets.

Responsibilities

Own and execute U.S. commercial strategies for biosimilars and 505(b)(2) assets in alignment with enterprise objectives.
Lead lifecycle management, pricing strategy, and go‑to‑market planning for pipeline and marketed products.
Drive launch readiness, execution, and post‑launch optimization to maximize performance and impact.
Lead commercial diligence and strategic assessments for licensing, partnerships, and portfolio expansion within the biosimilars and 505(b)(2) space.
Provide clear market perspectives to inform investment decisions and pipeline prioritization.
Partner closely with Regulatory, R&D, Manufacturing, Supply Chain, Medical Affairs, Finance, and Market Access teams to ensure seamless execution from development through launch.
Build strong relationships with payers, GPOs, specialty pharmacies, providers, and channel partners to optimize access, reimbursement, and utilization.
Build and lead a high‑performing commercial organization focused on accountability, collaboration, and sustainable growth.